ホーム / ニュース / Certara、早期およびトランスレーショナルな医薬品開発のための新規 Simcyp™ Discovery シミュレーターを発表

Certara、早期およびトランスレーショナルな医薬品開発のための新規 Simcyp™ Discovery シミュレーターを発表

Advances lead optimization, first-in-human dose prediction and formulation development

ニュージャージー州プリンストン 2022 年 6 月 28 日: Certara (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Discovery Simulator, a new software designed for scientists working in small molecule drug discovery and translational research. Derived from the industry-leading Simcyp Simulator, Simcyp Discovery increases confidence in early-stage development decisions using physiologically-based pharmacokinetic (PBPK) modeling and simulation. 

“We are pleased to offer our new Simcyp Discovery Simulator to help identify and move forward the most promising new drug candidates for further investigation,” said William F. Feehery, Ph.D., CEO of Certara. “The failure rate from preclinical to clinical studies is high with only a third of drugs entering into human testing.  With Simcyp Discovery, scientists can apply PBPK earlier in the development process to better inform critical decisions and reduce risk of drug failure.”

Simcyp Discovery includes PBPK models for mouse, rat, dog, monkey and humans, enabling researchers to predict first-in-human (FIH) pharmacokinetics and understand how investigational drugs may behave before going into clinical trials, a regulatory requirement. The software also supports early formulation simulations and flags potential drug-drug interactions (DDI) with a new static DDI calculator informed by regulatory guidelines from the U.S. Food and Drug Administration, European Medicines Agency, and Japan’s Pharmaceuticals and Medical Devices Agency. Additionally, Simcyp Discovery supports rapid batch processing and screening of drug candidates.

“The role of modeling and simulation in drug discovery and development continues to expand and evolve. At Certara, we are committed to advancing our technology to meet the needs of researchers throughout the entire drug lifecycle,” said Robert Aspbury, Ph.D., president of Simcyp at Certara. “Simcyp Discovery will help improve translational research and impact patient safety and efficacy.”

For more information about Simcyp Discovery, please visit: https://www.certara.com/simcyp-overview/simcyp-discovery/


Certara(サターラ) について

サターラは、独自のバイオシミュレーションソフトウェア、テクノロジー、コンサルティングサービスを通して、従来の創薬・医薬品開発に変革をもたらすことをミッションとしています。製薬、教育機関、規制当局のお客様 2,000人以上、6262ヵ国にてサターラの技術やサービスが活用されています。

本件に関するお問合わせ先

Jieun W. Choe
jieun.choe@certara.com

メディア関係の皆様:

赤津 笑美
emi.akatsu@certara.com
ariane.lovell@finnpartners.com

投資家の皆様:

David Deuchler
ir@certara.com

トップに戻る
Powered by Translations.com GlobalLink OneLink Software